American CryoStem Announces Patient Recruitment and Additional Sub-Investigator for its Post-Concussion Syndrome (PCS) Phase I Clinical Trial

December 1, 2020 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / December 1, 2020 / American CryoStem Corporation (OTC PINK:CRYO) a clinical-stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has commenced recruiting subjects for its IND Phase I Clinical Trial and added an additional sub-investigator to the ATCELL™ Clinical Trial team. The Company's autologous mesenchymal stem cell...

Read more

Molecular Partners to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

November 30, 2020 11:45 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / November 30, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that Dr. Patrick Amstutz, CEO of Molecular Partners, will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 3:55 - 4:25 PM Eastern Time...

Read more

Edesa Biotech Enrolls First Patient in COVID-19 Study

November 30, 2020 7:30 AM

TORONTO, ON / ACCESSWIRE / November 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2/Phase3 clinical trial evaluating the company's investigational drug, EB05, as a therapy for hospitalized COVID-19 patients. EB05 is a clinical-stage monoclonal antibody that Edesa believes could regulate the overactive and dysfunctional immune...

Read more

Binovi Announces Debt Settlement

November 27, 2020 8:00 PM

TORONTO, ON AND NEW YORK, NY / ACCESSWIRE / November 27, 2020 / Binovi Technologies Corp., (Binovi) (TSXV:VISN)(OTCQB:BNVIF), a leader is neuro-vision performance technology, announces that, subject to the approval of the TSX Venture Exchange, it intends to settle $214,088.70 in outstanding indebtedness to an arms-length party through the issuance of an aggregate of 1,223,364 common shares at a price of $ 0.175 per share. The shares issued...

Read more

Hancock Jaffe Announces Reverse Stock Split

November 27, 2020 8:30 AM

IRVINE, CA / ACCESSWIRE / November 27, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 25 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on November 30, 2020 and...

Read more

Richard Sorgnard Identifies How Technology Can Address Neuropathic Disorders

November 25, 2020 1:50 PM

Technology is Helping Patients Improve Pain and Overcome Neuropathic Disorders, Explains Richard Sorgnard LAS VEGAS, NV / ACCESSWIRE / November 25, 2020 / Technology in the medical industry has been used for decades. However, it is mostly used to aid doctors. Now, electric signal generation technology is being used to aid patients. Richard Sorgnard has developed a number of tools to help with neuropathic disorders. Richard Sorgnard is...

Read more

Havn Life Sciences Announces $5.46 Million Warrant Exercise

November 24, 2020 8:00 AM

VANCOUVER, BC / ACCESSWIRE / November 24, 2020 / Havn Life Sciences Inc. (CNSX:HAVN)(FSE:5NP) (the "Company" or "Havn Life") is pleased to announce that 10,927,856 common share purchase warrants ("Warrants") have been exercised ("Exercise"), resulting in proceeds to the Company of $5.46 million. The Warrants had originally been issued by the Company pursuant to a private placement that closed on June 5,...

Read more

Midatech Pharma PLC Announces MTX110 presented at 2020 Annual SNO Conference

November 24, 2020 2:00 AM

ABINGDON, OXFORDSHIRE / ACCESSWIRE / November 24, 2020 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to note that the latest research on MTX110 was presented by its collaborators at the recent annual meeting of the Society of Neuro-Oncology (SNO2020 Virtual Conference). Links to the Abstracts and Posters are provided...

Read more

HF Enterprises Inc. Announces Pricing of Initial Public Offering

November 23, 2020 10:40 PM

BETHESDA, MD / ACCESSWIRE / November 23, 2020 / HF Enterprises Inc. (NASDAQ:HFEN)(the "Company"), a diversified holding company principally engaged through its subsidiaries in property development, digital transformation technology and biohealth activities, today announced the pricing of its initial public offering of 2,160,000 shares of its common stock at a public offering price of $7.00 per share for gross proceeds of...

Read more

Apollo Endosurgery to Present at Piper Sandler Healthcare Conference

November 23, 2020 11:40 AM

AUSTIN, TX / ACCESSWIRE / November 23, 2020 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that its management team will participate in the 32nd Annual Piper Sandler Healthcare Conference. December 1-2, 2020 32nd Annual Piper Sandler Healthcare Conference Apollo management will participate in virtual one on...

Read more

Hillstream BioPharma’s HSB-888 Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Osteosarcoma

November 23, 2020 9:45 AM

Osteosarcoma remains the most common primary pediatric bone malignancy mostly occurring in adolescents for which treatment has remained essentially unchanged for the past three decades Osteosarcoma is a highly-aggressive tumor with metastatic disease either at diagnosis or at the time of recurrence portending a poor prognosis with five-year survival rate survival below 30% HSB-888 could be more efficacious, safer and a more tolerable...

Read more

Hancock Jaffe's VenoValve(R) Results Featured in Journal of Vascular Surgery Venous and Lymphatic Disorders

November 23, 2020 8:30 AM

Preliminary First-in-Human Study Results Published in Peer-Reviewed Journal IRVINE, CA / ACCESSWIRE / November 23, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Journal of Vascular Surgery Venous and Lymphatic Disorders, published a paper featuring interim results from the VenoValve first-in-human trial. The article entitled "Human...

Read more

MedTechVIP Launches First Virtual and In-Person Event "MedTechVIP in Middleburg"

November 23, 2020 8:00 AM

The First MedTechVIP Family Office Event Designed to Educate, Inspire, and Connect Investors with Biodesign Innovations - A Meeting Where Clinical Impact Meets Economic Returns MIDDLEBURG, VA / ACCESSWIRE / November 23, 2020 / MedTechVIP is pleased to announce the first in an event series, "MedTechVIP in Middleburg ", an in-person and virtual gathering dedicated to highlighting Biodesign as an asset class. The event is geared as an...

Read more

Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin(R) Therapeutic Candidate MP0420

November 23, 2020 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / November 23, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that a first cohort of eight healthy volunteers has been dosed in a Phase 1 first-in-human study of MP0420 (ensovibep), a DARPin® therapeutic candidate for the potential treatment and...

Read more

American Screening LLC Facilitates Efficient Decision-Making with Vast Selection of Rapid Drug Tests

November 19, 2020 11:35 PM

SHREVEPORT, LA / ACCESSWIRE / November 19, 2020 / Despite the social progress and economic prosperity achieved in the past few decades, certain issues remain a common challenge for nations worldwide. One of them is illicit drug use, which has been straining healthcare budgets, affecting workplace productivity, and endangering public safety. However, medical and technological advances have enabled government agencies, healthcare professionals,...

Read more

ITOCO Releases Current List of "Time Of Presentation" (TOP) Verification Solutions That Address Virus Testing on Its Blog

November 19, 2020 7:44 AM

TORONTO, ON / ACCESSWIRE / November 19, 2020 / ITOCO INC. (OTC PINK:ITMC) has released a list of companies and organizations addressing Virus testing through time-of-presentation (TOP) solutions. TOP solutions provide updated status of vaccination and/or testing at point of contact. Time of Presentation verification solutions refer to systems which uses verification to prove that a person presenting themselves to an event, physical...

Read more

Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85M

November 19, 2020 6:30 AM

Asset Sale in Preparation for US National Securities Exchange Listing KELOWNA, BC / ACCESSWIRE / November 19, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, has entered a definitive asset purchase agreement (the "Agreement"), through its wholly owned subsidiary Lexaria Canpharm ULC ("CanPharm"), to sell certain...

Read more

NovAccess Global Secures Worldwide Rights to Approved Patent

November 18, 2020 9:00 AM

Provides advancement for its immunotherapy technology against brain tumors into human clinical trials CLEVELAND, OH / ACCESSWIRE / November 18, 2020 / NovAccess Global Inc. (OTC PINK:XSNX) (the "Company" or "NovAccess"), a cancer therapeutics company with operations in biotechnology is thrilled to announce that it has an unlimited use license to an approved US Patent # 9764014, which was obtained in September 2020 when...

Read more

Bio Lab Naturals, Inc.'s Subsidiary Signs Exclusive Distribution Agreement

November 18, 2020 8:00 AM

GREENWOOD VILLAGE, CO / ACCESSWIRE / November 18, 2020 / Bio Lab Naturals, Inc. ("BLAB" or the "Company") (OTCQB:BLAB) announces today that its subsidiary, Prime Time Live, Inc. ("PTL") signed an Exclusive Distribution Agreement on November 13, 2020 with Insane Impact, LLC ("Insane Impact"), an Iowa limited liability company, to act as Insane Impact's exclusive distributor of Insane Impact...

Read more

Lumira Ventures Appoints Special Advisors and Venture Partner

November 18, 2020 5:00 AM

Veteran Pharmaceutical Industry Executives Will Advise Portfolio Companies and Investment Team TORONTO, ON / ACCESSWIRE / November 18, 2020 / Lumira Ventures, a leading North American healthcare venture capital firm, today announced the appointment of Theodore Witek, Jr., DrPH, MBA and Daniel Billen, PhD to the role of Special Advisor, and Sena Biswas, PhD, MBA as Venture Partner. "We are excited to welcome Ted, Daniel and Sena to the...

Read more